146 related articles for article (PubMed ID: 37403773)
21. Idiopathic nonhistaminergic angioedema successfully treated with ecallantide, icatibant, and C1 esterase inhibitor replacement.
Stahl MC; Harris CK; Matto S; Bernstein JA
J Allergy Clin Immunol Pract; 2014; 2(6):818-9. PubMed ID: 25439384
[No Abstract] [Full Text] [Related]
22. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
Hide M; Ohsawa I; Nurse C; Yu M;
J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
[TBL] [Abstract][Full Text] [Related]
23. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
[No Abstract] [Full Text] [Related]
24. Idiopathic Nonhistaminergic Acquired Angioedema Versus Hereditary Angioedema.
Andrási N; Veszeli N; Kőhalmi KV; Csuka D; Temesszentandrási G; Varga L; Farkas H
J Allergy Clin Immunol Pract; 2018; 6(4):1205-1208. PubMed ID: 29715562
[TBL] [Abstract][Full Text] [Related]
25. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema.
Lumry WR; Maurer M; Weller K; Riedl MA; Watt M; Yu M; Devercelli G; Meunier J; Banerji A;
Ann Allergy Asthma Immunol; 2023 Jul; 131(1):101-108.e3. PubMed ID: 37028510
[TBL] [Abstract][Full Text] [Related]
26. Idiopathic nonhistaminergic angioedema.
Cicardi M; Bergamaschini L; Zingale LC; Gioffré D; Agostoni A
Am J Med; 1999 Jun; 106(6):650-4. PubMed ID: 10378623
[TBL] [Abstract][Full Text] [Related]
27. Classification of angioedema without wheals.
Prieto-García A; Marcos C; Caballero T;
Ann Allergy Asthma Immunol; 2016 Feb; 116(2):177. PubMed ID: 26815713
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
Wang Y; Marier JF; Kassir N; Chang C; Martin P
Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
[TBL] [Abstract][Full Text] [Related]
29. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
[TBL] [Abstract][Full Text] [Related]
30. Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.
Watt M; Malmenas M; Haeussler K
J Comp Eff Res; 2024 May; 13(5):e240041. PubMed ID: 38606574
[No Abstract] [Full Text] [Related]
31. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
[TBL] [Abstract][Full Text] [Related]
32. An Atypical Case of Idiopathic Nonhistaminergic Angioedema With Anti-C1-INH Antibodies.
Bova M; Suffritti C; Joseph K; Caccia S; Gelderman KA; Berra S; Loffredo S; Santacroce R; Petraroli A; Roem-Haagsma D; Margaglione M; Spadaro G; Kaplan AP
J Investig Allergol Clin Immunol; 2022 Dec; 32(6):498-500. PubMed ID: 35166675
[No Abstract] [Full Text] [Related]
33. Lanadelumab: A Review in Hereditary Angioedema.
Syed YY
Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
[TBL] [Abstract][Full Text] [Related]
34. Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate.
Bork K; Staubach-Renz P; Hardt J
Orphanet J Rare Dis; 2019 Mar; 14(1):65. PubMed ID: 30866985
[TBL] [Abstract][Full Text] [Related]
35. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
36. [Lanadelumab : Future plasma-independent subcutaneous prophylaxis for bradykinin-mediated angioedema?].
Wedi B
Hautarzt; 2017 Jul; 68(7):585-587. PubMed ID: 28560465
[No Abstract] [Full Text] [Related]
37. Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing.
Adatia A; Ritchie B
J Allergy Clin Immunol Glob; 2023 May; 2(2):100087. PubMed ID: 37780787
[TBL] [Abstract][Full Text] [Related]
38. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.
Lumry WR; Weller K; Magerl M; Banerji A; Longhurst HJ; Riedl MA; Lewis HB; Lu P; Devercelli G; Jain G; Maurer M;
Allergy; 2021 Apr; 76(4):1188-1198. PubMed ID: 33258114
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study.
Johnston DT; Busse PJ; Riedl MA; Maurer M; Anderson J; Nurse C; Inhaber N; Yu M; Banerji A;
Clin Exp Allergy; 2021 Oct; 51(10):1391-1395. PubMed ID: 34166549
[No Abstract] [Full Text] [Related]
40. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
